XML 21 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Marketable Securities
3 Months Ended
Mar. 31, 2017
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following as of March 31, 2017 and December 31, 2016:

 

 

March 31, 2017

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Money market accounts

$

6

 

 

$

 

 

$

 

 

$

6

 

   Corporate debt securities

 

40,407

 

 

 

 

 

 

(132

)

 

 

40,275

 

   Less: Cash equivalents

 

(6

)

 

 

 

 

 

 

 

 

(6

)

      Total marketable securities

$

40,407

 

 

$

 

 

$

(132

)

 

$

40,275

 

 

 

December 31, 2016

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   Money market accounts

$

1,580

 

 

$

 

 

$

 

 

$

1,580

 

   Corporate debt securities

 

38,728

 

 

 

3

 

 

 

(163

)

 

 

38,568

 

   Less: Cash equivalents

 

(1,580

)

 

 

 

 

 

 

 

 

(1,580

)

      Total marketable securities

$

38,728

 

 

$

3

 

 

$

(163

)

 

$

38,568

 

 

As of March 31, 2017 and December 31, 2016, the contractual maturities of the Company’s marketable securities less than one year were $20.6 million and $13.0 million, respectively, and the contractual maturities of the Company’s marketable securities greater than one year and less than five years were $19.6 million and $25.6 million, respectively. Management determined that the gross unrealized losses of $132,000 on the Company’s marketable securities as of March 31, 2017 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $163,000 as of December 31, 2016. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of March 31, 2017. There were no sales of marketable securities in any of the periods presented.